10.28.2024 - POLA
Oct 28, 2024•11 min•Ep. 238
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more.
Check out the website and subscribe to the newsletter!
Founders & Lead Authors: Laura Dover & Caleb Dulaney
Podcast Host: Sam Marcrom
For the best experience, listen in Metacast app for iOS or Android